Response to Lavin et al's paper: Cutaneous T-Cell Lymphoma after Dupilumab Use: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System
J Invest Dermatol. 2025 May 30:S0022-202X(25)00543-3.
doi: 10.1016/j.jid.2025.05.022.
Online ahead of print.
1 Guy's and St Thomas NHS trust, St John's Institute of Dermatology, London, United KIngdom.
2 London School of Hygiene and Tropical Medicine, London, United KIngdom.
3 Guy's and St Thomas NHS trust, St John's Institute of Dermatology, London, United KIngdom; King's College London, London, United KIngdom.
4 Guy's and St Thomas NHS trust, St John's Institute of Dermatology, London, United KIngdom; King's College London, London, United KIngdom. Electronic address: sean.whittaker@kcl.ac.uk.
5 Guy's and St Thomas NHS trust, St John's Institute of Dermatology, London, United KIngdom; London School of Hygiene and Tropical Medicine, London, United KIngdom.